Alexey Vinogradov
Direktor/Vorstandsmitglied bei XENETIC BIOSCIENCES, INC.
Vermögen: 70 532 $ am 30.04.2024
Profil
Dr. Alexey A.
Vinogradov is an Independent Non-Executive Director at Xenetic Biosciences, Inc. and a Director-Operations & Business Development at Cantreva LLC.
He is on the Board of Directors at Pharmsynthez PJSC, Xenetic Biosciences, Inc. and Avelas Biosciences, Inc. Dr. Vinogradov was previously employed as a General Manager by Togas Middle East LLC, an Independent Director by Argos Therapeutics, Inc., a Branch Manager by Togas Group LLC, a Managing Partner by Pharmstandard Ventures, and an Investment Manager by Bioprocess Capital Partners Ltd.
He received his doctorate degree from Moscow State University Lomonosov.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 18 679 ( 1,21% ) | 70 532 $ | 30.04.2024 |
Aktive Positionen von Alexey Vinogradov
| Unternehmen | Position | Beginn |
|---|---|---|
| XENETIC BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 19.07.2019 |
| PHARMSYNTHEZ | Direktor/Vorstandsmitglied | 03.08.2023 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | 14.03.2017 |
| Cantreva LLC | Geschäftsführer | 01.09.2017 |
Ehemalige bekannte Positionen von Alexey Vinogradov
| Unternehmen | Position | Ende |
|---|---|---|
| Togas Middle East LLC | Corporate Officer/Principal | 01.05.2017 |
| Togas Group LLC | Corporate Officer/Principal | 01.11.2016 |
| ARGOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.06.2016 |
Bioprocess Capital Partners Ltd.
 Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Private Equity Investor | 31.12.2010 |
Pharmstandard Ventures
 Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Vorstandsvorsitzender | - |
Ausbildung von Alexey Vinogradov
| Moscow State University Lomonosov | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XENETIC BIOSCIENCES, INC. | Health Technology |
| PHARMSYNTHEZ | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Bioprocess Capital Partners Ltd.
Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Finance |
Pharmstandard Ventures
Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Finance |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
| Cantreva LLC | |
| Togas Middle East LLC | |
| Togas Group LLC |
